Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beta Bionics (BBNX) Change in Accured Expenses (2024 - 2025)

Beta Bionics' Change in Accured Expenses history spans 2 years, with the latest figure at $5.9 million for Q4 2025.

  • For Q4 2025, Change in Accured Expenses rose 64.16% year-over-year to $5.9 million; the TTM value through Dec 2025 reached $7.4 million, up 8.57%, while the annual FY2025 figure was $7.4 million, 8.57% up from the prior year.
  • Change in Accured Expenses for Q4 2025 was $5.9 million at Beta Bionics, up from $4.1 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $5.9 million in Q4 2025 and bottomed at -$5.3 million in Q1 2025.